Belmay/TFF merger
This article was originally published in The Rose Sheet
Executive Summary
New York City-based fragrance supplier Belmay and Amityville, N.Y.-based fragrance developer Technology Flavors & Fragrances will have combined sales of more than $60 mil. following planned merger announced Nov. 20. Agreement would call for Belmay to purchase 75% of TFF, which would change its name to Belmay/TFF and reconstitute its board of directors, firm says. Belmay President/CEO Ted Kesten will be appointed chairman/CEO of combined entity, while TFF Chairman/CEO Philip Rosner will become vice chair. Merger will help transform TFF into "world-class global developer and manufacturer of flavors and fragrances" by providing access to Belmay's solid infrastructure and international operations, TFF says. Move follows restructuring announcement by TFF prompted by consecutive sales losses ("The Rose Sheet" Nov. 19, In Brief)...
You may also be interested in...
TFF/Belmay terminate proposed merger
Fragrance developer Technology Flavors & Fragrances and fragrance supplier Belmay have terminated proposed merger discussions in a mutual agreement, the two companies announce Jan. 16. "Although the TFF/Belmay combination would have created a much larger entity in terms of sales volume...the proposed merger was not in the interest of our shareholders," Amityville, N.Y.-based TFF states. The two firms entered into the proposed agreement in November; merger was projected to result in combined sales of $60 mil. for the two firms (11"The Rose Sheet" Nov. 26, 2001, In Brief)...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.